AstraZeneca has successfully completed its acquisition of Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca’s cell therapy ambition.
 
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy.
 
GC012F is a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases including systemic lupus erythematosus (SLE).
 
Gracell will operate as a wholly owned subsidiary of AstraZeneca, with operations in China and the US.
 
This news comes weeks after AstraZeneca invested $300 million in a facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply.

Other Industry Acquisitions